CENTESSA PHARMACEUTICALS PLC CNTA 深 滬
已收盤 08-01 16:00:00 美东时间
16.81
-0.360
-2.10%
華盛通- 最 高17.45
- 今 開17.06
- 成交量 85.12万股
- 最 低 16.67
- 昨 收 17.17
- 總市值 22.53亿
- 52周最高 19.09
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 9.60
- 委 比 -22.78%
- 總股本 1.34亿
- 歷史最高 26.90
- 量 比 0.63
- 振 幅 4.54%
- 歷史最低 2.885
- 每 手 1
- 風險率 2.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅57.1%！Macquarie上调Marathon Digital目标价至26美元，维持"跑赢大市"评级
今日重点评级关注：Macquarie：维持Marathon Digital"跑赢大市"评级，目标价从19美元升至26美元；巴克莱：维持Universal Health Services"超配"评级，目标价从257美元升至259美元
07-31 09:05
Chardan Capital Maintains Buy on Centessa Pharmaceuticals, Maintains $30 Price Target
Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.
07-31 06:05
Truist Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $30
Truist Securities analyst Danielle Brill initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $30.
07-21 19:54
Nxera Pharma Secures $4.8 Million Milestone Payment from Centessa
Sosei Group ( ($JP:4565) ) just unveiled an update. Nxera Pharma announced it w...
07-04 07:52
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Centessa Pharmaceuticals has received FDA clearance to initiate a Phase 1 clinical study of ORX142, a novel OX2R agonist for treating neurological and neurodegenerative disorders. ORX142 is the second drug candidate from the company's orexin franchise and aims to address significant unmet needs in these areas. The Phase 1 study will assess safety, tolerability, and pharmacokinetics in healthy volunteers, with early proof-of-concept data expected ...
06-16 13:00
Centessa Pharmaceuticals Appoints New Chief Accounting Officer
Centessa Pharmaceuticals ( ($CNTA) ) has issued an update. On May 27, 2025, Cen...
05-29 20:26
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
Needham Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $35
Needham analyst Ami Fadia initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $35.
05-28 18:25
Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
Centessa Pharmaceuticals Plc ( ($CNTA) ) has released its Q1 earnings. Here is ...
05-15 12:24
Centessa Pharmaceuticals Q1 EPS $(0.20) Beats $(0.37) Estimate, Sales $15.00M
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.37) by 45.95 percent. This is a 47.37 percent increase over losses of $(0.38) per
05-14 19:04
